I-Mab Forms $150 Million China Immunotherapy Partnership With MacroGenics

I-Mab Biopharma, a Shanghai oncology company, in-licensed greater China rights to a novel immunotherapy developed by MacroGenics of Maryland. The candidate, enoblituzumab, is an investigational B7-H3 antibody. A member of the family of B7 immune regulator proteins, B7-H3 is expressed by several types of tumors. I-Mab agreed to a $150 million package of upfront and milestone payments, plus royalties. It will lead greater China trials of the candidate and also participate in MacroGenics global tests, currently testing enoblituzumab in patients with head and neck cancer. More details.... Stock Symbol: (NSDQ: MGNX) Share this with colleagues: // //